Background: Methylenedioxymethamphetamine (MDMA; ecstasy) is used recreationally and has been investigated as an adjunct to psychotherapy. Most acute effects of MDMA can be attributed to activation of the serotonin (5-hydroxytryptamine [5-HT]) system. Genetic variants, such as single-nucleotide polymorphisms (SNPs) and polymorphic regions in 5-HT system genes, may contribute to interindividual differences in the acute effects of MDMA.
Introduction
3,4-Methylenedioxymethamphetamine (MDMA; molly, ecstasy) is popularly used for its empathic and euphoric effects. Recent research indicates that MDMA may also be useful as an adjunct to psychotherapy in patients with posttraumatic stress disorder (PTSD; [1] [2] [3] . MDMA mainly acts as a releaser of serotonin (5-hydroxytryptamine ) and norepinephrine and to a lesser extent dopamine 4, 5 . Compared with amphetamine, typical effects of MDMA can be predominantly attributed to activation of the 5-HT system [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Key components of the 5-HT system include tryptophan hydroxylase (TPH), the 5-HT transporter (SERT), and 5-HT1A, 5-HT1B, and 5-HT2A receptors. Manipulations of 5-HT system targets could modulate the effects of MDMA. Pharmacological inhibition of the SERT significantly reduced the psychotropic and most physiological effects of MDMA 11, 13, 16, 17 . Inhibition of the 5-HT2A receptor also attenuated some of the acute effects of MDMA 12, 18, 19 , whereas 5HT1 receptor inhibition had no effect 20, 21 .
The role of the 5-HT system in the acute effects of MDMA has been well studied, but little is known about the ways in which interindividual variations of genes that encode targets that are implicated in the mechanism of action of MDMA or its metabolism influence the response to MDMA. For example, genetic variations of the enzymes that are involved in MDMA metabolism (mainly CYP2D6) have been shown to affect plasma levels of MDMA and its metabolites in several clinical studies [22] [23] [24] and modulate the pharmacokinetics and some of the pharmacodynamic effects of MDMA. Genetic variants of pharmacological targets of MDMA may also alter its pharmacodynamic effects, but the few studies that have been published to date have reported no or only minimal effects, including potential chance findings [25] [26] [27] [28] .
The major target of MDMA in the 5-HT system is the SERT 4, 5, 11, 29 . A common repeat polymorphism in the promoter region of the SLC6A4 gene (5-HTTLPR), which encodes the 4 SERT, comprises two variants with long (L) and short (S) alleles. Each variant includes a number of SNP variants. However, in the Caucasian population, only the rs25331 SNP is important 30 . In vitro, cells with the LL polymorphism have approximately double the uptake activity of cells that carry one or two copies of the S allele 31 . In humans, individuals with the L allele and G variant of rs25331 present the same low-expressing phenotypes as S-allele carriers [32] [33] [34] in L-allele carriers than in SS individuals and more sedation in the SS group than in L-allele carriers 35 . Furthermore, regular ecstasy users who were carriers of the S allele presented a higher risk of mood disorders and emotional and cognitive dysfunction and performed worse on a verbal fluency task [36] [37] [38] [39] . Finally, MDMA produced a two-fold increase in SERT gene expression, and this increase tended to be more pronounced in homozygous L carriers 40 . In contrast, no association was found between the 5-HTTLPR polymorphism and MDMAinduced impairments in memory function or MDMA-induced changes in cortisol levels 41, 42 .
MDMA indirectly and partially also directly interacts with 5-HT receptors 5, 10, 43 .
Single-nucleotide polymorphisms of the genes that encode 5-HT receptors could influence the effects of MDMA, but this possibility has not yet been investigated. The rs6295 SNP of the HTR1A gene, which encodes the 5-HT1A receptor, may play a role in substance use disorder 44 .
Female homozygous carriers of the G allele of the rs6295 who suffered from major depressive 5 disorder benefited more from treatment with a SERT inhibitor than carriers of the C allele 45 .
The rs6296 SNP of HTR1B, which encodes the 5-HT1B receptor, was found to influence childhood aggressive behavior. Individuals who were homozygous for the C-allele were more aggressive than those who carried the G allele 46 . 5-HT2A receptors are one of the most researched targets of psychoactive drugs. The C allele of the rs6313 SNP of HTR2A, which encodes the 5-HT2A receptor, is associated with lower expression and was found to be associated with suicide, a lower ability to adopt the point of view of others, greater anxiety when observing pain, and communication problems [47] [48] [49] . However, the rs6313 SNP did not modulate cognitive dysfunction in chronic ecstasy users 38 .
The rate-limiting step in 5-HT biosynthesis is catalyzation by TPH, and MDMA inhibits TPH activity 50, 51 . Tryptophan hydroxylase has two isoforms: TPH1 and TPH2. The rs1800532 SNP of TPH1 has been reported to influence gene transcription, and the rare T allele was associated with a decrease in 5-HT synthesis 52 . The T allele has also been associated with SERT inhibitor treatment efficacy and the risk for bipolar disorder and alcohol dependence 53, 54 . Additionally, the rs7305115 SNP of TPH2 has been associated with susceptibility to suicide, in which the A allele was significantly less frequent in suicide attempters than in nonattempters 55, 56 .
The present study investigated whether the acute effects of MDMA are influenced by genetic variations within the serotonergic system. We evaluated whether the TPH1 rs1800532 and rs1799913 SNPs, TPH2 rs7305115 SNP, HTR1A rs6295 SNP, HTR1B rs6296 SNP, HTR2A rs6313 SNP, and SLC6A4 5-HTTLPR and rs25531 polymorphisms influence MDMAinduced subjective, emotional, empathic, cardiovascular, thermogenic, and adverse effects. We expected that the results of previous smaller studies that included some of these SNPs would be replicated 26, 35 .
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Results
Effects of the SNPs on the maximum response (Emax) to MDMA are shown in Table 1 . Supplementary Table S1 shows the data for the response to MDMA over time (AUEC). Supplementary Tables S2 and S3 show the uncorrected statistics for Emax and AUEC, respectively. Sex did not significantly alter the results. Talkative  N: 14, 61, 49  18±23  21±19  24±17  0.76  NS  NS  Appetite  N: 7, 33, 32  -3±32  -9±28  -6±34  0.07  NS  NS  Tired  N: 12, 54, 43  13±34  20±31  22±33  0.28  NS  NS  Fear  N: 7, 33, 32  -1±12  6±19  9±17  0.86  NS  NS  Happy  N: 12, 41, 28  27±21  28±18  29±20  0.05  NS  NS  Content  N: 12, 41, 28  27±22  30±17  32±19  0.28  NS  NS  Trust  N: 7, 28, 17  14±30  23±20  28±21  1.11  NS  NS  want to be 
Genotyping
The distribution of the alleles and genotypes did not differ from the distributions that were reported elsewhere in Caucasian cohorts (Ensembl database release 94, October 2018).
The minor allele frequencies for rs1800532 and rs1799913, rs7305115, rs6295, rs6296, rs6313, 
Subjective effects
On the tested VASs and AMRSs, MDMA significantly altered the Emax values for all reported parameters. With the exception of a decrease in "appetite," all of the parameters were increased by MDMA ( Fig 1) . The effects of serotonergic system gene polymorphisms on the subjective effects of MDMA are shown in Table 1 . Carriers of the HTR2A rs6313 A allele had higher ratings of "good drug effect," "trust," AMRS "well-being," "high-mood," and "dreaminess" compared with homozygous G-allele carriers (F1,121 = 6.93, p < 0.01, F1,49 = 6.07, p < 0.05, F1,121 = 5.68, p < 0.05, F1,121 = 6.04, p < 0.05, and F1,121 = 6.95, p < 0.01, respectively).
Individuals with the short allele of 5-HTTLPR had higher ratings of "good drug effect," "drug liking," and "closeness to others" and lower ratings of "bad drug effect" compared with the Nyholt correction for multiple comparisons indicated that the genetic polymorphisms had no significant effect on these subjective parameters. 
Adverse effects of MDMA
MDMA significantly increased LC scores after up to 6 h and up to 24 h (Table 1) .
Specifically, MDMA increased the acute and subacute scores for "lack of appetite," "nausea,"
and "dizziness." Individuals with the GG genotype of the TPH2 rs7305115 SNP suffered more often from acute "lack of appetite" than individuals with the AA genotype (mean ± SD: 0.36 ± 0.50 for AA vs. 0.76 ± 0.43 for GG; p = 0.017). Subjects with the A allele of the HTR2A rs6313 SNP felt less acute "dizziness" than subjects who were homozygous for the G allele (mean ± SD: 0.25 ± 0.44 for AA/AG vs. 0.55 ± 0.55 for GG; p = 0.0012). Nyholt correction for multiple comparisons indicated that the genetic polymorphisms had no significant effect on the adverse effects of MDMA. 
Discussion
The present study investigated the effects of interindividual differences in genes that encode the 5-HT system on MDMA-induced mood, empathogenic, cardiovascular, thermogenic, and adverse effects. Although genetic variants of 5 Another previous study also suggested that the 5-HTTLPR polymorphism may play an important role in modulating the risk of adverse effects of MDMA, mainly cardiovascular effects 35 . However, MDMA-induced cardiovascular effects were not influenced by 5-HT system gene variations in the present study, which was larger and more methodologically sound 2012), we used 125 mg MDMA, which is the dose that is also used in patients 1-3, 57, 58 . As shown in an earlier study, the 125 mg dose is stronger and produced greater good drug effects compared with the 75 mg dose 59 . 5-HT system genotypes may present more modulatory effects when MDMA is taken at a lower dose and not at higher doses, such as in therapeutic settings.
The present study has limitations. First, although this is the largest uniform cohort with mostly MDMA-naive healthy subjects, confirmation in studies with larger samples is needed, which is the case for all such genetic studies. The sample size was relatively small when considering the mostly small effect sizes for the influence of genetic variants on the MDMA response. Additionally, tests for empathy and emotion recognition were only completed by 69
subjects. However, we unlikely missed very large effect sizes for the influence of the tested genetic variants. Second, the study was conducted in mostly young and healthy volunteers.
Therefore, the findings cannot necessarily be generalized to other populations, such as psychiatric patients and elderly subjects. Third, SNPs of genes of other targets of MDMA may also be involved but were not tested in the present study. However, we corrected for the modulatory effects of known genetic variants that influence the metabolism of MDMA 22, 23 and also unequal proportions of MDMA concentrations between 5-HT genotypes by accounting for interindividual differences in plasma MDMA concentrations.
In light of recent efforts to use MDMA as an adjunct to psychotherapy for PTSD, modulators of the effects of MDMA should be identified. Our results showed that genetic variations of genes that encode the 5-HT system did not markedly influence the effects of MDMA in healthy subjects. Therefore, interactions between MDMA and 5-HT system genotypes may not be an important factor to consider when MDMA is used therapeutically or recreationally.
Methods
Study design
This was a pooled analysis of eight double-blind, placebo-controlled, crossover studies in healthy subjects that used similar methods 6, 14, [60] [61] [62] [63] [64] [65] . The studies included a total of 136 healthy subjects. Seven studies included 16 subjects each, for a total of 112 subjects, who received 125 mg MDMA twice, once alone and once after pretreatment with a medication 6, 14, Detailed pharmacokinetic and safety data from these studies have been reported elsewhere 22, 23, 59 . Test sessions were conducted in a quiet hospital research ward with no more than two research subjects present per session. The participants were comfortably lying in hospital beds and were mostly listening to music and not engaging in physical activities. MDMA was given without food in the fasting state in the morning at 8:00-9:00 AM. A small standardized lunch was served at 12:00-1:00 PM.
Subjects
A total of 136 healthy subjects of European descent, 18-44 years old (mean ± SD = 24.8 ± 4 years), were recruited from the University of Basel campus and participated in the study.
One genotyping sample was missing, three participants did not give consent for genotyping, and eight subjects participated twice (only participation that included all outcome measures was used), resulting in a final dataset from 124 subjects (64 women). The mean ± SD body weight was 68 ± 10 kg (range: 46-90 kg).
The exclusion criteria included a history of psychiatric disorders, physical illness, a lifetime history of illicit drug use more than five times (with the exception of past cannabis use), illicit drug use within the past 2 months, and illicit drug use during the study, determined by urine tests that were conducted before the test sessions as reported in detail elsewhere 14, [61] [62] [63] . Forty-two subjects had prior illicit drug experiences (1-5 times), of which 22 subjects had previously used MDMA (1-3 times), seven subjects had previously used amphetamine or methamphetamine (1 time), 10 subjects had previously used cocaine (1-3 times), six subjects had previously used lysergic acid diethylamide (1 time), and 11 subjects had previously used psilocybin (1-4 times).
Study drug (±)MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was administered orally in a single dose of 125 mg, prepared as gelatin capsules (Bichsel Laboratories, Interlaken, Switzerland). Similar amounts of MDMA are found in ecstasy pills 66 and have been used in clinical studies in patients 1, 2 . The doses were not adjusted for body weight or sex.
The dose per body weight (mean ± SD) was 1.9 ± 0.3 mg/kg (1.7 ± 0.2 mg/kg for men and 2.1 ± 0.3 mg/kg for women, range: 1.4-2.7 mg/kg).
Physiological effects
Blood pressure, heart rate, and body temperature were assessed repeatedly before and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA or placebo administration. Systolic and diastolic blood pressure and heart rate were measured using an automatic oscillometric device (OMRON Healthcare Europe NA, Hoofddorp, Netherlands). The measurements were performed in duplicate at an interval of 1 min and after a resting time of at least 10 min. The averages were calculated for the analysis. Mean arterial pressure (MAP) was calculated as diastolic blood pressure + (systolic blood pressurediastolic blood pressure) / 3. The rate pressure product (RPP) was calculated as systolic blood pressure  heart rate. Core (tympanic) temperature was measured using a Genius 2 ear thermometer (Tyco Healthcare Group LP, Watertown, NY, USA). In one study (n = 21), the 2 h time point was not used.
Acute and subacute adverse effects were assessed using the list of complaints (LC; 62, 67 . The scale consisted of 66 items, yielding a total adverse effects score (non-weighted sum of the item answers) that reliably measures physical and general discomfort. Additionally, serotonin-related adverse effects, such as "dizziness," "nausea," and "lack of appetite," were analyzed separately. Bruxism (item 66, a common side effect of MDMA) was included in the LC that was used in 92 subjects. The LC was administered 3-6 h (acute adverse effects up to 6 h) and 24 h (subacute adverse effects up to 24 h) after MDMA or placebo administration.
Subjective effects
To assess subjective effects, a Visual Analog Scale (VAS) was presented as a 100 mm horizontal line (0-100%), marked from "not at all" on the left to "extremely" on the right. The
VASs for "closeness to others," "happy," "content," "trust," "want to be hugged," and "want to hug," were bidirectional (±50%). "Trust," "want to be hugged," "want to hug," "want to be alone," and "want to be with others," were assessed in 52 subjects. "Appetite," and "fear," were assessed in 72 subjects. "Happy," and "content," were assessed in 81 subjects. "Tired" was assessed in 109 subjects 7 . The scale was administered before and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA or placebo administration. The 60-item Adjective Mood Rating Scale (AMRS; 68 was administered 1 h before and 1.25, 2, and 5 h after drug administration.
Emotion recognition
To measure emotion recognition, we used the Facial Emotion Recognition Task (FERT), which is sensitive to the effects of MDMA 6, 8, 64, 69, 70 and other serotonergic substances 71 . The task included 10 neutral faces and 160 faces that expressed one of four basic emotions (happiness, sadness, anger, and fear), with pictures morphed between 0% (neutral) and 100% in 10% steps. Two female and two male pictures were used for each of the four emotions. The stimuli were presented in random order for 500 ms and then were replaced by the rating screen where the participants had to indicate the correct emotion. The outcome measure was accuracy (proportion correct) and misclassification (emotions that were indicated incorrectly). The FERT was performed 90 min after drug administration. FERT data were available from 68 subjects.
Empathy
The Multifaceted Empathy Test (MET) is a reliable and valid task that assesses the cognitive and emotional aspects of empathy 72 . The MET is sensitive to oxytocin 73 , MDMA 7, 8, 20, 74 , and other psychoactive substances 71, 75 . The computer-assisted test consisted of 40 photographs that showed people in emotionally charged situations. To assess cognitive empathy, the participants were required to infer the mental state of the subject in each scene and indicate the correct mental state from a list of four responses. Cognitive empathy was defined as the percentage of correct responses relative to total responses. To measure emotional empathy, the subjects were asked to rate how much they were feeling for an individual in each scene (i.e., explicit emotional empathy) and how much they were aroused by each scene (i.e., implicit emotional empathy) on a 1-9 point scale. The latter rating provides an inherent additional assessment of emotional empathy, which is considered to reduce the likelihood of socially desirable answers. The three aspects of empathy were each tested with 20 stimuli with positive valence and 20 stimuli with negative valence, resulting in a total of 120 trials. The MET was performed 90-180 min after drug administration. MET data were available from 68
subjects.
Plasma concentrations of MDMA 20 Plasma levels of MDMA were determined before and 0.5, 1, 1.5, 2, 3, 4, and 6 h after drug administration 64 .
Genotyping
Genomic DNA was extracted from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hombrechtikon, Switzerland) and automated QIAcube system. Genotyping was performed using commercial TaqMan SNP genotyping assays (LuBio Science, Lucerne, Switzerland) and TaqMan Genotyping Master Mix. Fluorescence was detected using the ViiA7 real-time polymerase chain reaction (PCR) system. We assayed the following SNPs: TPH1 rs1800532 (assay: C___8940793_10) and rs1799913 (assay: C___2645661_10), TPH2 rs7305115 (assay: C___8376164_10), HTR1A rs6295 (assay: C__11904666_10), HTR1B rs6296 (C___2523534_20), and HTR2A rs6313 (assay: C___3042197_1_). We also used the following method to genotype the The LG and S alleles should express an identical phenotype [32] [33] [34] . Accordingly, three groups were defined: group 1 (LGLG, LGS, and SS) vs. group 2 (LALG, and LAS) vs. group 3 (LALA). The genotypes of TPH1 rs1800532 and rs1799913 were in total linkage disequilibrium; therefore, only the results for rs1800532 are reported.
Statistical analysis
The statistical analyses were performed using Statistica 12 software (StatSoft, Tulsa, OK, USA). For repeatedly measured data, peak effects (Emax) and areas under the effect-time curve (AUEC) from 0-6 h values were determined for MDMA and placebo. Differences in Emax and AUEC values (Δ; MDMA-placebo) were then analyzed using one-way analysis of variance (ANOVA), with genotype as the between-group factor, followed by the Tukey post hoc test.
To ensure that modulatory effects of genotype over time were not missed, ΔAUEC values were tested accordingly in an additional analysis. The level of significance was set at p < 0.05. The
Nyholt correction method was used to account for multiple comparisons and displayed separately in all tables 76 . We thereby corrected for the 19 subjective effects (VAS+AMRS), 3 Alcohol acutely enhances decoding of positive emotions and emotional concern for positive stimuli and facilitates the viewing of sexual images, Psychopharmacology 234, 41-51. 29 Supplementary Table S1 . Effects of polymorphisms in the serotonergic system on the response to 125mg MDMA (mean±SD and statistics) corrected with MDMA AUC6 
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